GLP-1 Hair Loss: What the Drug Labels Say, and Why Biotin Is the Wrong Answer

Search for what to take for hair loss on a GLP-1 and you’ll get a page of supplements. Almost none of those pages mention that the manufacturers already counted this, published the numbers, and said what they associate it with. It’s in the prescribing information, and it says something the supplement aisle rarely mentions.

What do the drug labels say about GLP-1 hair loss?

On the Zepbound label, hair loss is a counted adverse reaction in section 6.1: 5% at the 5 mg dose, 4% at 10 mg and 5% at 15 mg, against 1% on placebo. On the Wegovy label, the higher-dose study reports 1.0% on placebo, 3.3% at 2.4 mg, and 5.8% at 7.2 mg.

Then both labels say the same thing, in almost the same words. Zepbound’s reads: “Hair loss adverse reactions in ZEPBOUND-treated patients were associated with weight reduction.” Wegovy’s says the same of its own patients.

The manufacturers aren’t blaming a vitamin deficiency. They’re blaming the weight loss, the thing the drug is for.

Why is hair loss on the Wegovy label and not the Ozempic one?

This is the detail that gives the game away, and it’s almost never mentioned.

Wegovy and Ozempic are the same molecule. Semaglutide, both of them. But on Ozempic’s label, alopecia appears only under section 6.2, Postmarketing Experience: a single line under “Skin and Subcutaneous Tissue”, with no percentage and no placebo arm. It has been reported. It was never counted as an adverse reaction in Ozempic’s own trials.

The difference between the two labels isn’t chemistry. It’s dose and indication: the obesity programmes went higher and produced more weight loss, and they measured this. That’s exactly what you’d expect if the trigger were the rate of weight loss rather than the drug molecule. It’s also exactly what the dose-response inside the Wegovy programme shows, climbing from 1.0% to 3.3% to 5.8% as the dose rises.

It’s overwhelmingly happening to women

The single most searched version of this question adds one word: women. The label answers it directly, and the size of the gap is startling.

At the top Wegovy dose, 8.4% of women reported hair loss against 0.2% of men. In that same trial the 2.4 mg arm was 5.4% of women and no men, though in the larger pool of 2.4 mg studies the label reports separately it was 4% of women and 0.9% of men. Zepbound’s label reports the same shape across its two pivotal studies: 7.1% of female patients versus 0.5% of male patients, against a placebo arm of 1.3% female and no male patients.

Two things belong beside those numbers. The headline figures come from Wegovy’s maximum 7.2 mg dose; 2.4 mg is the recommended maintenance dosage, and the label reports 3.3% there. And at 7.2 mg the label records one event leading to permanent discontinuation, one to temporary interruption and five to dose reduction. There were none in the 2.4 mg or placebo groups.

If you’re a woman who noticed more hair in the shower a few months into treatment, you’re not imagining it and you’re not an outlier. You’re in the group this happens to.

What’s actually happening to the hair?

The pattern associated with rapid weight loss is telogen effluvium: a large share of follicles shifts out of the growing phase at once, and sheds together some months later. It’s the same shedding documented after bariatric surgery, serious illness and aggressive calorie restriction.

Two features matter for anyone living through it. It lags its trigger by roughly three months, so it typically shows up well after the change that caused it. And it’s characteristically self-limiting, resolving as the follicle cycle normalises.

One number from the Zepbound label is worth sitting with: across both pivotal studies, no patient taking the drug stopped because of hair loss. The only participant who discontinued for that reason was in the placebo group. That’s not a claim that it’s trivial, because it clearly distresses people. But it does say something about how it played out for those who kept going.

Does biotin help?

Biotin is the default answer almost everywhere you look. It’s the wrong one, for two separate reasons.

It hasn’t been shown to work in people who aren’t deficient

A review of the published evidence for biotin in hair loss identified 18 reported cases of benefit. Every one of them had an underlying pathology: an inherited enzyme disorder, brittle nail syndrome, or a real dietary deficiency. The authors’ conclusion is blunt: biotin “has no proven efficacy in hair and nail growth of healthy individuals.”

And biotin deficiency isn’t among the shortfalls associated with GLP-1 use. The large claims analysis of 461,382 patients found vitamin D deficiency leading by a wide margin, with B vitamins and nutritional anaemia behind it. Biotin has no separate line in it. It’s vitamin B7, and a biotin deficiency would be coded inside the “other vitamin B” category, which came to 2.6% within a year against vitamin D’s 13.6%. So that dataset can’t show biotin deficiency is absent, only that the category it hides in is a small share of what these patients are diagnosed with.

It can corrupt the tests used to investigate hair loss

This is the part that turns a harmless waste of money into something worth warning about.

The FDA has warned since 2017, and updated that warning since, that biotin “can significantly interfere with certain lab tests and cause incorrect test results which may go undetected.” The laboratory-medicine guidance puts the threshold at doses of 5 mg and above, which is ordinary territory for a hair supplement, and explains the direction of the error. Sandwich immunoassays such as TSH read falsely low. Competitive immunoassays such as free T4 read falsely high.

If you take biotin and have bloods drawn, tell the person ordering the test. That’s the FDA’s own recommendation, and it costs nothing.

What’s actually worth doing?

None of this means nothing helps. It means the useful levers aren’t the ones being advertised.

1. Talk to your prescriber about the rateBoth labels tie the reaction to weight reduction, and the Wegovy figures rise with dose. How fast you are losing is the variable most connected to the outcome, and it’s a clinical conversation: dose and titration aren’t things to adjust on your own.
2. Hit the protein target, in gramsThe 2025 joint advisory from four professional bodies notes that higher protein targets of 1.2 to 1.6 g/kg/day have been proposed during active weight reduction, while cautioning that basing them on actual body weight can significantly overestimate what someone needs. Work the number out with your prescriber or a dietitian. Protein is a real requirement for hair growth, and it is the nutrient most reliably squeezed out when appetite collapses.
3. Measure iron and vitamin D rather than guessingA real deficiency in either impairs hair growth, and vitamin D was the most commonly diagnosed deficiency in GLP-1 patients. Both are cheap blood tests. Correcting a measured shortfall is supported; supplementing a shortfall you don’t have isn’t.
4. Judge the timeline correctlyThe three months is the lag between the trigger and the start of the shedding, not how long until it stops. Regrowth can take several months to a year. Because telogen effluvium runs on its own schedule either way, a supplement started mid-shed will usually be in your cupboard when the shedding stops, which is how a great many products come to feel like they worked.
5. See a dermatologist for anything patchy or persistentIn a 2025 scoping review, only one of the nine included studies characterised the alopecia clinically: a retrospective cohort of 283 patients, in which 19 of the 35 cases were androgenetic alopecia and 10 were telogen effluvium. In that same cohort, 91.4% of the patients who lost hair already had a personal history of hair loss. It is a small, preliminary finding, but it suggests some of this is pattern hair loss being unmasked rather than temporary shedding. Those have different treatments, and neither is a gummy.

Where Tavita fits, and where it doesn’t

Tavita tracks protein in grams against your target and shows where iron and vitamin D are running against reference amounts, which covers the intake side of the list above. Our web stack checkerwill also tell you when things you’re already taking work against each other. The relevant one here is larger amounts of calcium reducing iron absorption. In the app, the drug interaction checker does the same for your medicines, checking each new one you add against everything else on your list.

It can’t measure your blood, diagnose alopecia, or tell you what dose to be on. We’re not going to pretend an app is the answer to a question the prescribing information and a dermatologist answer better.

Common questions